Oncologic therapy support via means of a dedicated mobile app (OPTIMISE-1)

• Verfasst von: El-Shafie, Rami [VerfasserIn]
• Verfasst von: Bougatf, Nina [VerfasserIn]
• Verfasst von: Sprave, Tetyana [VerfasserIn]
• Verfasst von: Kronsteiner, Dorothea [VerfasserIn]
• Verfasst von: Oetzel, Dieter [VerfasserIn]
• Verfasst von: Machmer, Timo [VerfasserIn]
• Verfasst von: Huber, Peter E. [VerfasserIn]
• Verfasst von: Debus, Jürgen [VerfasserIn]
• Verfasst von: Nicolay, Nils [VerfasserIn]
• Titel: Oncologic therapy support via means of a dedicated mobile app (OPTIMISE-1)
• Titelzusatz: protocol for a prospective pilot trial
• Verf.angabe: Rami A. El Shafie, Nina Bougatf, Tanja Sprave, Dorothea Weber, Dieter Oetzel, Timo Machmer, Peter E. Huber, Jürgen Debus, Nils H. Nicolay
• E-Jahr: 2018
• Jahr: 06.03.18
• Umfang: 8 S.
• Fussnoten: Gesehen am 15.08.2019
• Titel Quelle: Enthalten in: JMIR Research Protocols
• Ort Quelle: Toronto : [Verlag nicht ermittelbar], 2012
• Jahr Quelle: 2018
• Band/Heft Quelle: 7(2018,3) Artikel-Nummer e70, 8 Seiten
• ISSN Quelle: 1929-0748
• DOI: doi:10.2196/resprot.8915
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 167143787X

Abstract

Background: The increasing role of consumer electronics and Web-enabled mobile devices in the medical sector opens up promising possibilities for integrating novel technical solutions into therapy and patient support for oncologic illnesses. A recent survey carried out at Heidelberg University Hospital suggested a high acceptance among patients for an additional approach to patient care during radiotherapy based on patient-reported outcomes by a dedicated mobile app. Objective: The aim of this trial (OPTIMISE-1: Oncologic Therapy Support Via Means of a Dedicated Mobile App - A Prospective Feasibility Evaluation) is to prospectively evaluate the feasibility of employing a mobile app for the systematic support of radiooncological patients throughout the course of their radiotherapy by monitoring symptoms and patient performance, and facilitating the background-exchange of relevant information between patient and physician. Methods: The present single-center, prospective, exploratory trial, conducted at Heidelberg University Hospital, assesses the feasibility of integrating an app-based approach into patient-care during radiotherapy. Patients undergoing curative radiotherapy for thoracic or pelvic tumors will be surveyed regarding general performance, treatment-related quality of life (QoL) and symptoms, and their need to personally consult a physician by means of a mobile app during treatment. The primary endpoint of feasibility will be reached when 80% of the patients have successfully answered 80% of their respective questions scheduled for each treatment day. Furthermore, treatment-related patient satisfaction and health-related QoL is assessed by the Patient Satisfaction Questionnaire Short Form (PSQ-18) and the European Organization for Research and Treatment of Cancer (EORTC) questionnaires at the beginning (baseline) and end of radiotherapy, and at the first follow-up. Results: This trial will recruit 50 patients over a period of 12 months. Follow-up will be completed after 18 months, and publication of results is planned at 24 months after trial initiation. Conclusions: This study will serve as a basis for future studies aiming to exploit the constant innovation in mobile medical appliances and integrate novel patient-centered concepts into patient care in the context of radiotherapy. Trial Registration: ClinicalTrials.gov NCT03168048; https://clinicaltrials.gov/ct2/show/NCT03168048 (Archived at WebCite http://www.webcitation.org/6wtWGgi0X) [JMIR Res Protoc 2018;7(3):e70]